A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and tolerability of pirtobrutinib
(LOXO-305) and to look at the amount of the study drug, pirtobrutinib, that gets into the
blood stream and how long it takes the body to get rid of it when given in healthy adult
participants. For each participant, the total duration of the study will be 46 days,
including screening.